This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Quest PharmaTech Signs Exclusive License Agreement With UCLA For Anti - PSA IgE Technology; UCLA Researchers To Present Anti - PSA IgE Preclinical Data At The 2013 American Association For Cancer Research Conference

TSX Venture: QPT

EDMONTON, April 8, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.

The technology was developed by Professor Manuel Penichet and Dr. Tracy Daniels-Wells in collaboration with Dr. Christopher Nicodemus among others. It covers the use of immunotherapeutic IgE in development for treatment of patients with malignancies expressing the tumor-associated antigen PSA, which is associated with prostate cancer.

Dr. Tracy Daniels-Wells will present promising preclinical results obtained with the anti-PSA monoclonal IgE as a novel therapy for prostate cancer in the upcoming AACR meeting in Washington D.C. on April 9, 2013.  The data demonstrate the potential ability of the novel molecule to selectively open the circulation which may improve the ability of cytotoxic therapy to reach cancers. At the same time, the antibody can activate specific cellular immune responses directed against PSA originating in the tumor. The presentation includes a demonstration of antitumor activity in a PSA expressing tumor mouse model.

Quest is focusing its commercial efforts in the area of antibody mediated cancer immunotherapy with both IgG and IgE products. Quest holds numerous patents for the use of tumor associated monoclonal antibodies as immune modulators. "Both IgG and IgE technologies are complementary and provide a novel approach for enhancing the effectiveness of chemotherapy while activating specific immunity to fight the cancer" commented Dr. Madi R. Madiyalakan, CEO of the Company.

The licensed technology platform includes three pending patent applications. Under the license agreement, Quest is obligated to make an upfront fee, milestone and royalty payments to UCLA on future revenues.

About Quest PharmaTech Inc.

Quest PharmaTech is a publicly traded; Canadian based clinical stage company developing a portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, immune-adjuvants and photodynamic therapy. Quest has a body of clinical experience and a new appreciation of the obstacles and potential of combinatorial immunotherapeutic approaches to cancer by using either immunoglobulin G or E as immune modulators to enhance tumor specific immunity and clinical outcome.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs